- Healthcare Professionals
- Latest research
- Clinical trials
- TG Therapeutics 304
TG Therapeutics 304
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic
Trial overview
Topic
TG Therapeutics 304
Description
This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL).
Physicians
Contact
North Florida / Jacksonville
Astrid Corrales-Cruz